Teva Pharmaceutical Industries (TEVA) Research & Development (2017 - 2026)

Teva Pharmaceutical Industries has disclosed Research & Development across 10 years of filings, most recently posting $222.0 million for Q1 2026.

• Quarterly Research & Development fell 10.12% year-over-year to $222.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $989.0 million (down 1.4% YoY) and the FY2025 annual result came in at $1.0 billion, up 1.5% from the prior year.
• Research & Development declined to $222.0 million in Q1 2026, from $267.0 million in the prior quarter.
• Over five years, Research & Development peaked at $269.0 million in Q2 2024 and troughed at $175.0 million in Q3 2022.
• A 5-year average of $236.8 million and a median of $240.0 million in 2023 frame the typical range for Research & Development.
• Annual changes were most pronounced in 2022 — Research & Development slipped 21.17% — and 2023, when it surged 44.57%.
• Tracing TEVA's Research & Development over 5 years: stood at $210.0 million in 2022, then rose by 8.1% to $227.0 million in 2023, then grew by 8.81% to $247.0 million in 2024, then rose by 8.1% to $267.0 million in 2025, then slipped by 16.85% to $222.0 million in 2026.
• Business Quant data shows TEVA's Research & Development at $222.0 million in Q1 2026, $267.0 million in Q4 2025, and $256.0 million in Q3 2025.